- Home
- XGN vs PLRX Comparison
XGN vs PLRX Comparison
Compare XGN & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | PLRX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 79.9M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XGN | PLRX |
|---|---|---|
| Price | $3.59 | $1.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $11.00 | $3.75 |
| AVG Volume (30 Days) | 354.2K | ★ 722.9K |
| Earning Date | 04-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.99 | N/A |
| Revenue Next Year | $11.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $1.09 |
| 52 Week High | $12.23 | $1.95 |
Technical Indicators
Market Signals| Indicator | XGN | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 58.06 |
| Support Level | $3.15 | $1.12 |
| Resistance Level | $4.00 | $1.36 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 55.29 | 91.30 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.